These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26857783)

  • 61. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
    Hasegawa Y; Ando Y; Shimokata K
    Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
    [TBL] [Abstract][Full Text] [Related]  

  • 62. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
    Mehra R; Murren J; Chung G; Smith B; Psyrri A
    Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [UGT1A1 Genotyping for Proper Use of Irinotecan].
    Matsuoka A; Ando Y
    Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
    de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
    Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
    [TBL] [Abstract][Full Text] [Related]  

  • 68. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
    J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
    [No Abstract]   [Full Text] [Related]  

  • 70. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
    Ishikawa K; Kajita Y; Hasegawa Y; Noda Y; Yoshida J; Nabeshima T
    J Neurooncol; 2005 Sep; 74(3):283-6. PubMed ID: 16187025
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
    Yang Y; Zhou M; Hu M; Cui Y; Zhong Q; Liang L; Huang F
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e479-e489. PubMed ID: 29932297
    [TBL] [Abstract][Full Text] [Related]  

  • 74. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer.
    Zhou CF; Ma T; Su Y; Ye ZB; Ji J; Yu YY; Zhang J; Liu BY; Zhu ZG
    Anticancer Agents Med Chem; 2013 Feb; 13(2):235-41. PubMed ID: 22934695
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Relationship between UGT1A and irinotecan-related toxicity].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
    [No Abstract]   [Full Text] [Related]  

  • 76. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
    Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
    Innocenti F; Ratain MJ
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
    Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
    Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.